HUP9801140A2 - Antifungal composition - Google Patents

Antifungal composition

Info

Publication number
HUP9801140A2
HUP9801140A2 HU9801140A HUP9801140A HUP9801140A2 HU P9801140 A2 HUP9801140 A2 HU P9801140A2 HU 9801140 A HU9801140 A HU 9801140A HU P9801140 A HUP9801140 A HU P9801140A HU P9801140 A2 HUP9801140 A2 HU P9801140A2
Authority
HU
Hungary
Prior art keywords
stone
infusions
fungal
treatment
azole
Prior art date
Application number
HU9801140A
Other languages
Hungarian (hu)
Inventor
Josef Gottfried Meingassner
Neil Stewart Ryder
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP9801140A2 publication Critical patent/HUP9801140A2/en
Publication of HUP9801140A3 publication Critical patent/HUP9801140A3/en
Publication of HU224920B1 publication Critical patent/HU224920B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A találmány gőmbaellenes hatású kőmpőzíciókra, azők alkalmazására,ilyen kőmpőzíciók előállítására szőlgáló eljárásra, valamintgőmbafertőzések kezelésére alkalmas eljárásra vőnatőzik. A találmányszerinti, azőlőkkal szemben ellenállóképes élesztőgőmbatörzsek általembereken előidézett gőmbás fertőzések kezelésére alkalmas,gőmbaellenes hatású kőmpőzíciók terbinafint és 14a-metil-demetiláz-inhibitőr- ként azőlt tartalmaznak. Az azőlszármazék(ők)kal szemben ellenállóképessé vált gőmbatörzsekáltal őkőzőtt azőlrezisztens gőmbafertőzéseket úgy kezelik a találmányszerinti módszerrel, hőgy a találmány szerinti, gőmbaellenes hatásúkőmpőzíciókat a gyógyhatás eléréséhez megfelelő mennyiségben jűttatjákbe az ilyen kezelésre rászőrűló betegek szervezetébe. A találmány szerinti kőmpőzíciók előnye, hőgy alkalmazás esetén azazőlszármazék(ők)kal szemben rezisztenssé vált gőmbatörzsek általelőidézett gőmbás megbetegedések is kezelhetők. ŕThe invention relates to stone infusions with anthelmintic effect, to their application, to a process for the production of such stone infusions, and to a process suitable for the treatment of anthelmintic infections. According to the invention, the anti-fungal stone infusions suitable for the treatment of fungal infections caused by yeast fungi strains resistant to fungi contain terbinafine and 14a-methyldemethylase inhibitor, fumigant. Azole-resistant anthrax infections caused by anthrax strains that have become resistant to the azole derivative(s) are treated with the method according to the invention, in which the anti-azole stone compositions according to the invention are injected into the body of patients requiring such treatment in an amount sufficient to achieve a therapeutic effect. The advantage of the stone infusions according to the invention is that fungal diseases caused by fungal strains that have become resistant to the herbal derivative(s) can also be treated when applied with heat. ŕ

HU9801140A 1995-05-12 1996-05-10 Use of an antifungal composition HU224920B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509631.9A GB9509631D0 (en) 1995-05-12 1995-05-12 Antifungal combination
PCT/EP1996/002022 WO1996035423A1 (en) 1995-05-12 1996-05-10 Antifungal composition

Publications (3)

Publication Number Publication Date
HUP9801140A2 true HUP9801140A2 (en) 1999-01-28
HUP9801140A3 HUP9801140A3 (en) 2000-07-28
HU224920B1 HU224920B1 (en) 2006-04-28

Family

ID=10774361

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801140A HU224920B1 (en) 1995-05-12 1996-05-10 Use of an antifungal composition

Country Status (26)

Country Link
US (1) US5985906A (en)
EP (1) EP0824350B1 (en)
JP (1) JPH11504931A (en)
KR (1) KR100443535B1 (en)
CN (1) CN1100539C (en)
AT (1) ATE246504T1 (en)
AU (1) AU712914B2 (en)
CA (1) CA2219651C (en)
CY (1) CY2496B1 (en)
CZ (1) CZ291144B6 (en)
DE (1) DE69629367T2 (en)
DK (1) DK0824350T3 (en)
ES (1) ES2205042T3 (en)
FI (1) FI120079B (en)
GB (1) GB9509631D0 (en)
HK (1) HK1016064A1 (en)
HU (1) HU224920B1 (en)
IL (2) IL118219A0 (en)
MX (1) MX9708699A (en)
NO (1) NO317030B1 (en)
PL (1) PL322749A1 (en)
PT (1) PT824350E (en)
SK (1) SK150797A3 (en)
TW (1) TW464492B (en)
WO (1) WO1996035423A1 (en)
ZA (1) ZA963754B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
AU783158B2 (en) * 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
GB0001315D0 (en) * 2000-01-20 2000-03-08 Novartis Ag Organic compounds
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
US6673373B2 (en) 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1706128B1 (en) 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
BRPI0607910A2 (en) 2005-04-07 2010-03-23 Toyama Chemical Co Ltd pharmaceutical composition for treating authentic infections, and method of using an arylamidine derivative or a salt thereof
NZ575714A (en) 2006-10-06 2011-05-27 Toyama Chemical Co Ltd Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent
EP2121572A2 (en) * 2006-12-08 2009-11-25 Auspex Pharmaceuticals Inc. Preparation and utility of substituted allylamines
CA2711765A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP3008192B1 (en) 2013-06-11 2019-07-17 Takara Bio USA, Inc. Protein enriched microvesicles and methods of making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
GB2099818A (en) * 1981-06-06 1982-12-15 Pfizer Ltd Triazoles
US4782059A (en) * 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
JP2581707B2 (en) * 1987-10-02 1997-02-12 科研製薬株式会社 Antifungal composition
CA2016738A1 (en) * 1989-06-08 1990-12-08 Philippe Guerry Substituted aminoalkylbenzene derivatives
JPH0338521A (en) * 1989-07-05 1991-02-19 Maruho Kk Antifungal composition
JPH0338522A (en) * 1989-07-05 1991-02-19 Maruho Kk Antifungal composition
CA2020888A1 (en) * 1989-07-27 1991-01-28 Philippe Guerry Substituted aminoalkoxybenzene derivatives
US5214046A (en) * 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
CA2044533A1 (en) * 1990-06-29 1991-12-30 Philippe Guerry Substituted aminoalkylbiphenyl derivatives
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
JP3038522U (en) 1996-12-05 1997-06-20 秀俊 筬 Cardboard box potpourri
JP3038521U (en) 1996-12-05 1997-06-20 啓次 小峰 Water-soluble fiber stick-like absorbent material for temporary excrement holder

Also Published As

Publication number Publication date
DK0824350T3 (en) 2003-11-03
IL118219A0 (en) 1996-09-12
US5985906A (en) 1999-11-16
CA2219651A1 (en) 1996-11-14
GB9509631D0 (en) 1995-07-05
FI120079B (en) 2009-06-30
CN1184427A (en) 1998-06-10
EP0824350B1 (en) 2003-08-06
SK150797A3 (en) 1998-05-06
ES2205042T3 (en) 2004-05-01
TW464492B (en) 2001-11-21
KR100443535B1 (en) 2004-12-17
KR19990014708A (en) 1999-02-25
CY2496B1 (en) 2005-09-02
PL322749A1 (en) 1998-02-16
CN1100539C (en) 2003-02-05
PT824350E (en) 2003-12-31
HU224920B1 (en) 2006-04-28
HK1016064A1 (en) 1999-10-29
IL118219A (en) 2001-08-26
ZA963754B (en) 1997-11-10
DE69629367D1 (en) 2003-09-11
HUP9801140A3 (en) 2000-07-28
FI973812A0 (en) 1997-09-26
AU712914B2 (en) 1999-11-18
NO317030B1 (en) 2004-07-26
ATE246504T1 (en) 2003-08-15
EP0824350A1 (en) 1998-02-25
AU5818396A (en) 1996-11-29
NO975134D0 (en) 1997-11-07
JPH11504931A (en) 1999-05-11
DE69629367T2 (en) 2004-06-09
NO975134L (en) 1997-11-07
FI973812A (en) 1997-11-11
MX9708699A (en) 1998-02-28
CA2219651C (en) 2007-03-27
CZ354797A3 (en) 1998-02-18
WO1996035423A1 (en) 1996-11-14
CZ291144B6 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
HUP9801140A2 (en) Antifungal composition
BRPI0514199A (en) method of effecting prophylaxis or treating a disease, pharmaceutical composition, monoclonal antibody, hybridoma cell, and method of screening an agent, humanizing monoclonal antibody 8a5 or monoclonal antibody 6h7 and producing a chimeric form of monoclonal antibody 8a5 or monoclonal antibody 6h7
WO2002043652A3 (en) Anti-proliferative drugs
NO20060307L (en) Use of the quinoazoline derivative ZD6474 in combination with platinum compounds and possibly ionizing radiation in the treatment of diseases associated with angiogenesis and / or ocular vascular permeability
BR0212689A (en) Fungicidal composition, control method and product
TR200102809T2 (en) Bacillus pumilus line for control of plant diseases
HK1083196A1 (en) Topical compositions having a natural ingredient and method of use
NO20045038L (en) Combination of a beta-2 adrenoceptor agonist and an amino sugar and their use in the treatment of immunomodulatory diseases
AU2001265151A1 (en) Method of stimulating hair growth
MD1651G2 (en) Fungi strains Nectria pityrodes Montagne possessing fungicidal properties and process for screening thereof, biofungicide, biofungicidal composition and method of fungicidal inhibition
NO20051261L (en) Morphine-6-glukuronidsalt
ZA202104960B (en) Methods of treating pain with a thiazoline anti-hyperalgesic
HK1087328A1 (en) Therapeutic composition for autoimmune conditions
HUP9802419A2 (en) Antigenic preparations
WO2007008904A3 (en) Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
ATE157255T1 (en) COMPOSITION FOR THE COMBAT OF DERMATOMYCOSIS AND THEIR PATHOGENS AS WELL AS SWEATING AND BODY ODOR
WO2019232203A3 (en) Methods and compositions to alleviate vascular permeability
WO2022221834A3 (en) Method for treating lung cancer and non-small cell lung cancer
Zaias et al. Superficial mycoses: treatment with a new, broad-spectrum antifungal agent: 1% clotrimazole solution
MX2023002776A (en) Glycoconjugates and medical uses thereof.
ATE284209T1 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF EYE DISEASES CAUSED BY BACTERIA, VIRUSES, FUNGI, YEAST AND/OR PROTOZOA
MX2022012001A (en) Preventative treatment of migraine.
WO2021097021A3 (en) Treatment and protection against aspergillus infection and aspergillosis disease
CY1106619T1 (en) METHOD OF PREPARING AN ISOLATED EXTRACT OF THE EUROPEAN-L CYCLAMINE PLANT AND ITS USE AS A THERAPEUTIC AGENT
WO2005094282A3 (en) Combination therapy comprising cloretazinetm

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: DERZSI KATALIN, S.B.G. & K. BUDAPESTI NEMZETKO, HU

FH92 Termination of representative

Representative=s name: DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

MM4A Lapse of definitive patent protection due to non-payment of fees